奥拉帕利联合同步放疗治疗软组织肉瘤的Ib期研究结果:法国肉瘤协作组研究
这项多中心Ib期试验评估奥拉帕利联合同步放疗治疗肢体或躯干壁软组织肉瘤,推荐II期剂量为奥拉帕利100 mg每日两次;可手术患者有利组织学反应率为33%、1年局部无复发生存率90.5%,不可手术患者中位无进展生存期7.7个月(95%CI 2.6-28.4个月),3级放射性皮炎最常见(34.1%),2例(4.8%)发生5级毒性。
要点
- 推荐II期剂量为奥拉帕利100 mg每日两次联合同步放疗。
- 可手术患者有利组织学反应率33%,1年局部无复发生存率90.5%。
- 不可手术患者中位无进展生存期7.7个月(95%CI 2.6-28.4个月),部分缓解20%、疾病稳定60%。
核心结论
- 奥拉帕利联合同步放疗对软组织肉瘤患者可行,但需严格筛选,避免肿瘤累及关键血管结构或手术高风险患者,以减少严重并发症。
- 需要进一步随机试验验证与单纯放疗相比的疗效和安全性。
研究设计与样本
- 多中心Ib期试验,评估奥拉帕利联合同步放疗治疗肢体或躯干壁软组织肉瘤。
- 2016年10月至2021年4月在五家法国中心共纳入41例患者。
- 剂量递增阶段奥拉帕利每日两次给药,剂量为25、50、100或150 mg。
- 放疗剂量:可手术肿瘤为50 Gy(25次),不可手术肿瘤为59.4 Gy(33次);可手术患者放疗仅为术前放疗。
- 主要目标为确定最大耐受剂量和推荐II期剂量,剂量递增采用时间-事件持续再评估法。
主要发现
- 推荐II期剂量为奥拉帕利100 mg每日两次。
- 可手术患者中33%观察到有利组织学反应,1年局部无复发生存率为90.5%。
- 不可手术患者中位无进展生存期为7.7个月(95%置信区间2.6-28.4个月),20%的病例达到部分缓解,60%为疾病稳定。
- 3级放射性皮炎是最常见的不良事件(34.1%),2例患者发生5级毒性(4.8%)。
关键数值与推荐
- 推荐II期剂量:奥拉帕利100 mg每日两次联合同步放疗。
- 可手术患者放疗剂量50 Gy(25次),不可手术患者59.4 Gy(33次)。
临床怎么用
- 作者认为奥拉帕利联合同步放疗对软组织肉瘤患者可行,但需严格筛选,避免肿瘤累及关键血管结构或手术高风险患者,以减少严重并发症。
- 作者建议需要进一步随机试验验证与单纯放疗相比的疗效和安全性。
局限性
- 需要进一步随机试验验证与单纯放疗相比的疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy is essential for locoregional control in resectable soft-tissue sarcoma and remains a key strategy for unresectable soft-tissue sarcoma. Poly-ADP-ribose polymerase inhibitors, such as olaparib, may enhance radiosensitivity by targeting DNA damage repair pathways. PATIENTS AND METHODS: This multicenter phase Ib trial evaluated the combination of olaparib and radiotherapy in soft-tissue sarcoma of the limbs or trunk wall. Olaparib was administered twice daily at doses of 25, 50, 100, or 150 mg during the dose-escalation phase. Radiotherapy consisted of 50 Gy (25 fractions) for resectable tumors or 59.4 Gy (33 fractions) for unresectable tumors. Radiotherapy was exclusively preoperative for operable patients. Primary objectives were to determine the maximum tolerated dose and recommended phase II dose. Dose escalation was conducted using the time-to-event continual reassessment method. Histological response was assessed in surgical cases, and RECIST 1.1 criteria were applied for non-surgical cases. RESULTS: Between October 2016 and April 2021, 41 patients were recruited across five French centers. The recommended phase II dose was identified as 100 mg olaparib twice daily. For operable patients, a favorable histological response was observed in 33% of patients, with a local relapse-free survival rate of 90.5% at 1 year. In contrast, among patients with inoperable tumors, the median progression-free survival was 7.7 months (95% confidence interval 2.6-28.4 months), with partial responses achieved in 20% of cases and stable disease in 60%. Grade 3 radiation dermatitis was the most frequent adverse event (34.1%), and two patients experienced grade 5 toxicity (4.8%). CONCLUSION: The combination of olaparib and radiotherapy is feasible for soft-tissue sarcoma patients but requires stringent selection, avoiding patients with tumors involving critical vascular structures or those at high surgical risk, to minimize severe complications. Further randomized trials are warranted to validate efficacy and safety compared with radiotherapy alone.
引用
- Sargos P, Sunyach MP, Ducassou A, et al. Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study. Ann Oncol. 2025. PMID: 39894354. doi:10.1016/j.annonc.2025.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。